8-K: enGene Reports First Quarter 2025 Financial Results and Provides Business Update

enGene Holdings Inc. announced its first quarter 2025 financial results, highlighting progress with the LEGEND study and a cash runway into 2027.

Summary

• enGene Holdings Inc. announced its financial results for the first quarter ended January 31, 2025.
• The company's LEGEND study, evaluating detalimogene in BCG-unresponsive NMIBC with CIS, is progressing, with additional data anticipated in the second half of 2025.
• A Biologics License Application (BLA) filing is planned for mid-2026 and remains on track.
• The company's cash and marketable securities totaled $272.8 million as of January 31, 2025, expected to provide a runway into 2027.
• Total operating expenses for the quarter were $26.6 million, compared to $10.8 million for the same period in 2024.
• Research and development expenses increased by $14.3 million due to rising manufacturing and clinical costs related to the LEGEND study and headcount costs.
• General and administrative expenses increased by $1.5 million, driven by increased headcount to support the company's operations as a publicly traded entity.
• Net loss attributable to common shareholders was approximately $24.6 million, or $0.48 per share, compared to $10.7 million, or $0.46 per share, for the same period in 2024.
• The increase in net loss is mainly attributed to the increase in operating expenses, partially offset by net interest income earned during the period.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is progressing with its clinical trials and has a solid cash runway, the increased net loss is a concern.

Positives

• The LEGEND study is progressing with trial site expansion into Europe and Asia.
• The BLA filing for detalimogene remains on track for mid-2026.
• The company has a strong cash position of $272.8 million, providing a runway into 2027.
• The LEGEND study protocol has been amended to include maintenance dosing, potentially improving durability of response.
• All four LEGEND cohorts are now open for enrollment.

Negatives

• Operating expenses increased significantly to $26.6 million, compared to $10.8 million in the same period last year.
• Net loss attributable to common shareholders increased to $24.6 million, or $0.48 per share, compared to $10.7 million, or $0.46 per share, in the same period last year.

Risks

• The company's ability to recruit and retain qualified scientific and management personnel could impact progress.
• Establishing clinical trial sites and enrolling patients in clinical trials may face challenges.
• Executing on clinical development plans and securing regulatory approval on anticipated timelines are subject to uncertainty.
• The company's actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements.

Future Outlook

The company expects to announce enrollment completion of LEGEND's pivotal cohort and provide additional updates on other LEGEND study cohorts during the remainder of 2025, and anticipates filing a BLA for detalimogene in mid-2026.

Management Comments

• With the expansion of LEGEND study sites into Europe and Asia, enrollment in our pivotal cohort continues to track in-line with our plan to file a BLA for detalimogene in mid-2026, said Ron Cooper, Chief Executive Officer of enGene.
• We continue to believe in detalimogene's opportunity to transform the treatment landscape of NMIBC through a unique and differentiated overall profile that is highly attractive to both patients and physicians due to its potential for tolerability, ease-of-use, and efficacy.

Industry Context

enGene is focused on addressing the high unmet medical need in Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a significant patient burden and high rates of recurrence in BCG-unresponsive patients, positioning detalimogene as a potential alternative to cystectomy.

Comparison to Industry Standards

• The standard treatment for high-risk NMIBC unresponsive to BCG is cystectomy, a life-altering procedure, which detalimogene aims to avoid.
• Other companies in the NMIBC space include those developing viral-based gene therapies, which enGene's DDX platform seeks to overcome with simplified handling and manufacturing.
• The Fast Track designation from the FDA highlights the unmet need in BCG-unresponsive NMIBC, similar to other companies pursuing novel therapies in this area.

Stakeholder Impact

• Shareholders are impacted by the increased net loss, but also by the potential of detalimogene and the company's cash position.
• Patients with NMIBC could benefit from detalimogene as a potential alternative to cystectomy.
• Employees are impacted by the increased headcount and the company's progress in clinical trials.

Next Steps

• The company plans to announce enrollment completion of LEGEND's pivotal cohort.
• The company plans to provide additional updates on other LEGEND study cohorts during the remainder of 2025.
• The company plans to file a Biologics License Application (BLA) for detalimogene in mid-2026.

Key Dates